Nav: Home

Randomized penumbra 3D trial of next generation stent retriever meets primary endpoints

July 27, 2016

BOSTON, Mass. - July 27, 2016 - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that the Penumbra 3D Trial successfully met the primary trial endpoints, demonstrating non-inferiority in both safety and efficacy of the company's next-generation stent retriever, Penumbra 3D Revascularization Device, when used with Penumbra System aspiration devices compared to Penumbra System aspiration devices alone. The data were presented in the Late Breaking Abstract Presentations session today at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting in Boston, Massachusetts.

Results showed non-inferior revascularization rates according to the FDA-defined primary effectiveness measure of TICI 2-3 in the Penumbra 3D Revascularization Device with Penumbra System aspiration devices arm (3D+aspiration device arm) compared to the Penumbra System aspiration devices only arm (aspiration device-only arm) (88.5 percent vs. 85.9 percent). In addition, the more strictly defined revascularization measure, TICI 2b/3, showed non-inferiority between the 3D+aspiration device arm and the aspiration device-only arm (83.9 percent vs 74.1 percent). The primary safety endpoints - device-related serious adverse events (SAEs) and procedure-related SAEs - were not statistically different between the two arms (p=1.0 and p=0.4920, respectively).

"The results of the Penumbra 3D Trial speak positively on the use of Penumbra's 3D Revascularization Device in combination with the Penumbra System aspiration devices, as well as on the use of Penumbra System aspiration devices alone," said Donald Frei, MD, lead investigator of the study and director, NeuroInterventional Surgery at Radiology Imaging Associates/Swedish Medical Center in Englewood, Colorado. "The data also suggest that the revascularization rate in the Penumbra 3D plus aspiration device arm and the aspiration device-only arm - 83.9 and 74.1 percent, respectively - compare favorably to the 71 percent revascularization rate published in the HERMES meta-analysis of five major randomized controlled trials in acute ischemic stroke."

Patients in both arms experienced similar rates of return to functional independence (mRS ? 2 at 90 days): 41.6 percent in the 3D+aspiration device arm and 48.8 percent in the aspiration device-only arm (p=0.4260). These clinical outcomes were obtained without the benefit of selecting patients using imaging techniques designed to detect viable brain tissue.

"The trial results are encouraging for our Penumbra 3D Revascularization Device, and we are focused on continuing our plan to pursue regulatory submission by the end of this year," said Adam Elsesser, chairman and chief executive officer of Penumbra. "Furthermore, the broader implications of the data support frontline use of the Penumbra System direct aspiration devices in the revascularization of stroke patients."
-end-
About the Penumbra 3D Trial

The Penumbra 3D Trial was a prospective, randomized controlled non-inferiority study that compared the safety and efficacy of the Penumbra 3D Revascularization Device, used in conjunction with Penumbra System aspiration devices, to that of Penumbra System aspiration devices alone for the endovascular treatment of acute ischemic stroke patients with a large vessel occlusion. The primary study endpoints included core lab-adjudicated angiographic revascularization and safety. A total of 198 patients were randomized at 25 U.S. centers. The Penumbra 3D Revascularization Device is approved for investigational use only in the United States.

About the Penumbra System

The Penumbra System consists of large diameter, highly flexible, and reliably trackable reperfusion catheters that utilize the full aspiration power of the Penumbra Pump MAX™ through its Hi-Flow Aspiration Tubing. This integrated, proprietary system removes stroke-causing occlusions safely and effectively. The next generation Penumbra 3D Revascularization Device is designed to be used with the Penumbra System's family of reperfusion catheters. It features innovative three-dimensional chambers within the lumen to enable secure clot engagement while minimizing contact with the vessel wall. The majority of Penumbra System aspiration devices used in the 3D Trial included 4MAX™, 5MAX™ and 5MAXACE™ reperfusion catheters and separators.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc.

Forward-Looking Statements

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2015. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Merryman Communications

Related Data Articles:

Data centers use less energy than you think
Using the most detailed model to date of global data center energy use, researchers found that massive efficiency gains by data centers have kept energy use roughly flat over the past decade.
Storing data in music
Researchers at ETH Zurich have developed a technique for embedding data in music and transmitting it to a smartphone.
Life data economics: calling for new models to assess the value of human data
After the collapse of the blockchain bubble a number of research organisations are developing platforms to enable individual ownership of life data and establish the data valuation and pricing models.
Geoscience data group urges all scientific disciplines to make data open and accessible
Institutions, science funders, data repositories, publishers, researchers and scientific societies from all scientific disciplines must work together to ensure all scientific data are easy to find, access and use, according to a new commentary in Nature by members of the Enabling FAIR Data Steering Committee.
Democratizing data science
MIT researchers are hoping to advance the democratization of data science with a new tool for nonstatisticians that automatically generates models for analyzing raw data.
Getting the most out of atmospheric data analysis
An international team including researchers from Kanazawa University used a new approach to analyze an atmospheric data set spanning 18 years for the investigation of new-particle formation.
Ecologists ask: Should we be more transparent with data?
In a new Ecological Applications article, authors Stephen M. Powers and Stephanie E.
Should you share data of threatened species?
Scientists and conservationists have continually called for location data to be turned off in wildlife photos and publications to help preserve species but new research suggests there could be more to be gained by sharing a rare find, rather than obscuring it, in certain circumstances.
Futuristic data storage
The development of high-density data storage devices requires the highest possible density of elements in an array made up of individual nanomagnets.
Making data matter
The advent of 3-D printing has made it possible to take imaging data and print it into physical representations, but the process of doing so has been prohibitively time-intensive and costly.
More Data News and Data Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Clint Smith
The killing of George Floyd by a police officer has sparked massive protests nationwide. This hour, writer and scholar Clint Smith reflects on this moment, through conversation, letters, and poetry.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Nina
Producer Tracie Hunte stumbled into a duet between Nina Simone and the sounds of protest outside her apartment. Then she discovered a performance by Nina on April 7, 1968 - three days after the assassination of Dr. Martin Luther King Jr. Tracie talks about what Nina's music, born during another time when our country was facing questions that seemed to have no answer, meant then and why it still resonates today.  Listen to Nina's brother, Samuel Waymon, talk about that April 7th concert here.